46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
1 citations
,
November 2018 in “immuneACCESS” This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.
4 citations
,
June 2025 in “Cell Reports” In this study using the C3H/HeJ mouse model of alopecia areata, researchers found that hyperexpanded CD8+ T cell clones were sufficient to initiate disease, establishing a causal link between T cell clonality and pathogenicity.
July 2026 in “Journal of Investigative Dermatology” Alopecia totalis/universalis involves more intense immune activity and inflammation than patchy alopecia areata.
January 2025 in “International Journal of Pharma Medicine and Biological Sciences” This study examined interactions between immune cells and dermal papilla cells in a patient with alopecia areata using single-cell RNA sequencing; it identified specific T cell subtypes and ligand-receptor pairs that may contribute to hair cycle disruption through inflammation.